85216 Federal Register / Vol. 89, No. 207 / Friday, October 25, 2024 / Notices 

CDC requests OMB approval for an 

estimated 1,564 annual burden hours. 

There is no cost to respondents other 

than their time to participate. 

ESTIMATED ANNUALIZED BURDEN HOURS

Form name Type of respondent Number of 

respondents 

Number 

responses per 

respondent 

Avg. burden 

per 

response 

(in hrs.) 

Total 

burden 

(in hrs.) 

Triazole-resistant Aspergillus fumigatus Case Report Form State and Local Health Departments .... 15 15 0.5 113 

Coccidioidomycosis Case Report Form ................................ State and Local Health Departments .... 10 25 1.0 250 

Private Sectors ...................................... 3 10 1.0 30 

Histoplasmosis Case Report Form ....................................... State and Local Health Departments .... 10 25 1.0 250 

Private Sectors ...................................... 3 10 1.0 30 

Blastomycosis Case Report Form ........................................ State and Local Health Departments .... 10 25 1.0 250 

Private Sectors ...................................... 3 10 1.0 30 

Candida auris Case Report Form ......................................... State and Local Health Departments .... 15 20 0.75 225 

Private Sectors ...................................... 3 10 0.75 23 

Antifungal-resistant dermatophytosis case report form ........ State and Local Health Departments .... 10 10 0.5 50 

Chromoblastomycosis case report form ............................... Private Sectors ...................................... 25 10 0.5 125 

Mycetoma case report form .................................................. Private Sectors ...................................... 25 5 0.5 63 

Sporotrichosis case report form ............................................ Private Sectors ...................................... 25 10 0.5 125 

Total ............................................................................... ............................................................... ...................... .......................... .................... 1,564 

Jeffrey M. Zirger, 

Lead, Information Collection Review Office, 

Office of Public Health Ethics and 

Regulations, Office of Science, Centers for 

Disease Control and Prevention. 

[FR Doc. 2024–24922 Filed 10–24–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Meeting of the Lead Exposure and 

Prevention Advisory Committee 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention announces the following 

meeting for the Lead Exposure and 

Prevention Advisory Committee 

(LEPAC). This virtual meeting is open to 

the public. Advance registration by 

December 4, 2024, is needed to receive 

the information to join the meeting. The 

registration link is provided in the 

addresses section below. 

DATES: The meeting will be held on 

December 11, 2024 from 11 a.m. to 5 

p.m., EST. 

ADDRESSES: Register in advance https:// 

events.gcc.teams.microsoft.com/event/ 

0e538aa3-bc82-43e9-89ee-d997b498c

fe6@9ce70869-60db-44fd-abe8-d27670

77fc8f to receive information to join the 

meeting. 

FOR FURTHER INFORMATION CONTACT: Paul 

Allwood, Ph.D., M.P.H., Designated 

Federal Officer, National Center for 

Environmental Health, Centers for 

Disease Control and Prevention, 4770 

Buford Highway, Atlanta, Georgia 

30341, Telephone: 770–488–6774; 

Email: LEPAC@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Background: The Lead Exposure and 

Prevention Advisory Committee was 

established under Section 2203 of 

Public Law 114–322, the Water 

Infrastructure Improvements for the 

Nation Act; 42 U.S.C. 300j–21, Registry 

for Lead Exposure and Prevention 

Advisory Committee. 

Purpose: The LEPAC is charged with 

providing advice and guidance to the 

Secretary, Department of Health and 

Human Services (HHS), and the 

Director, CDC and Administrator, 

ATSDR, on (1) reviewing Federal 

programs and services available to 

individual communities exposed to 

lead; (2) reviewing current research on 

lead exposure to identify additional 

research needs; (3) reviewing and 

identifying best practices, or the need 

for best practices regarding lead 

screening and the prevention of lead 

poisoning; (4) identifying effective 

services, including services relating to 

healthcare, education, and nutrition for 

individuals and communities affected 

by lead exposure and lead poisoning, 

including in consultation with, as 

appropriate, the lead exposure registry 

as established in Section 2203(b) of 

Public Law 114–322; and (5) 

undertaking any other review or 

activities that the Secretary determines 

to be appropriate. 

Matters to be Considered: The agenda 

will include presentations and 

discussions on the following topics: 

vote on the 2023 annual LEPAC report, 

report from the Preventing Lead 

Exposure in Adults workgroup, lead 

related updates from the LEPAC 

members, local perspective on 

improving blood lead testing, blood lead 

testing strategies. Agenda items are 

subject to change as priorities dictate. 

Public Participation 

Oral Public Comment: The public 

comment period is scheduled on 

December 11, 2024, from 12:30 p.m. 

until 12:50 p.m., EST. Individuals 

wishing to make a comment during the 

public comment period, please email 

your name, organization, and phone 

number by November 25, 2024, to 

LEPAC@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–24925 Filed 10–24–24; 8:45 am] 

BILLING CODE 4163–18–P 


ddrumheller on DSK120RN23PROD with NOTICES1